Osteoporosis medication use over time in the United States and Canada
- Published on 06/06/2025
- Reading time: 4 min.
Hayes Kaleen N. 1,2,3, Zullo Andrew R. 1,2, Berry Sarah D. 4,5, Oganisian Arman 6, Aggarwal Sulbh 3,7, Adegboye Michael 1, Cadarette Suzanne M. 3,7,8
1 https://ror.org/01xyp9n09 Department of Health Services, Policy, and Practice and Center for Gerontology and Healthcare Research Brown University School of Public Health 121 South Main Street Providence Rhode Island USA
2 https://ror.org/05gq02987 Department of Epidemiology Brown University School of Public Health Providence RI USA
3 https://ror.org/03dbr7087 Leslie Dan Faculty of Pharmacy University of Toronto Toronto Canada
4 https://ror.org/02vptss42 Hinda and Arthur Marcus Institute for Aging Research, Hebrew Seniorlife and Harvard Medical School Boston MA USA
5 https://ror.org/04drvxt59 Department of Medicine Beth Israel Deaconess Medical Center Boston MA USA
6 https://ror.org/05gq02987 Department of Biostatistics Brown University School of Public Health Providence RI USA
7 https://ror.org/05p6rhy72 ICES Toronto ON Canada
8 https://ror.org/03dbr7087 Dalla Lana School of Public Health University of Toronto Toronto Canada
Abstract
Summary Over 12 years in the US and 26 years in Ontario, Canada, we found major differences in osteoporosis medications used. In both countries, osteoporosis medication initiation has not returned to pre-2008 levels; however, denosumab use is increasing. Future work should determine whether targeted screening or undertreatment drives these trends.
Purpose Concerns about adverse events caused a rapid decline in osteoporosis medication use globally...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Rheumatology
Receive our newsletter to stay up to date with the latest news in Rheumatology
